I studie IV blev tocilizumab givet intravenøst hver 4. uge i kombination med andre DMARDs vs. placebo plus andre DMARDs.
In Study IV, tocilizumab was administered intravenously every 4 weeks in combination with other DMARDs vs. placebo and other DMARDs.